Capital International, Inc. Biogen Inc. Transaction History

Capital International, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $1.15 Million - $1.46 Million	-4,286 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$220.06 - $304.07 $1.36 Million - $1.88 Million	-6,176 Reduced 59.03%	4,286 $1.27 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $1.05 Million - $1.17 Million	-4,812 Reduced 31.5%	10,462 $2.44 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $2.53 Million - $2.78 Million	11,516 Added 306.44%	15,274 $3.57 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $109,655 - $171,513	506 Added 15.56%	3,758 $888,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $166,264 - $210,591	597 Added 22.49%	3,252 $979,000
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $779,269 - $1.02 Million	2,655 New	2,655 $938,000

1,022

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital International, Inc. with notifications on news.